BiQ: FDA Approves CARDAMYST for the Treatment of PSVT (MIST)
Earlier today, the FDA granted approval of CARDAMYST for the treatment of PSVT, congratulations to all BiQ Members who were long! This marks the 7th drug approval for the BiQAP and BiQ Members since it was launched last year. We're batting a 1000 so far, so let's keep it up in 2026!
I will share my thoughts on my game plan going forward in a separate article. Until then, have a great weekend, everyone!
Please refer to the BiQAP Live spreadsheet on the Active Portfolio page or the iQCS for additional information.
MIST share price at time of publication: $2.41
Not a BiQ Premium member, or have a friend who may be interested? Try BiQ Premium for $50 per month, or $250 (50% off) for the first year.
Biotech iQ is 100% subscriber supported. If you find this information helpful, please spread the word. You can also follow me on X @ Biotech iQ (_Biotech_iQ).
Biotech iQ is not an investment professional, and nothing on this page or this website should be considered investment advice. Please consult with a licensed investment professional as necessary. Past performance is not indicative of future results.
Member discussion